Monoclonal antibody · Antagonist of interleukin-4 receptor alpha (IL4R) · developed by Sunshine Guojian Pharmaceutical Co.
Anti-interleukin-4 receptor alpha monoclonal antibody is an antibody that binds the interleukin-4 receptor alpha chain, a human protein, and is given by subcutaneous injection. It is studied in atopic dermatitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06324812 | Phase 1/2 | Dermatitis, Atopic | Completed | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dermatitis, Atopic
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →